Drugs / XB010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06545331 | Aug 2024 → Nov 2026 expected | esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma +1 | Exelixis | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XB010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06545331 ↗ |
| Route | Intravenous | “IV administration of XB010” NCT06545331 ↗ |